微信小陈
微信小章| 产品名称： | H69AR |
|---|---|
| 商品货号： | TS212074 |
| Organism： | Homo sapiens, human |
| Tissue： | lung |
| Cell Type： | epithelial |
| Product Format： | frozen |
| Morphology： | epithelial |
| Culture Properties： | adherent |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | carcinoma; small cell lung cancer; multidrug resistant |
| Age： | 55 years adult |
| Gender： | male |
| Ethnicity： | Caucasian |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | The multiple drug resistant cell line H69AR was established from NCI-H69 cells (ATCC HTB-119) that were grown in the presence of increasing concentrations of adriamycin (doxorubicin) over a total of 14 months. |
| Clinical Data： | 55 years adult Caucasian male |
| Tumorigenic： | Yes |
| Effects： | Yes, in nude mice |
| Comments： | The H69AR cell line is approximately 50-fold resistant to adriamycin as compared to the parental NCI-H69 cell line. The monoclonal antibodies QCRL-1 (ATCC HB-11765) and QCRL-3 (ATCC HB-11766) will react with fixed H69AR cells. The cell line is cross-resistant to anthracycline analogues including daunomycin, epirubicin, menogaril, and mitoxantrone as well as to acivicin, etoposide, gramicidin D, colchicine, and the Vinca alkaloids, vincristine and vinblastine. The cells display little or no cross-resistance to bleomycin, 5-fluorouracil, and carboplatin. They have a slight collateral sensitivity to 1-dehydrotestosterone and lidocaine.
The antibodies reacts with MRP (multidrug resistance protein), a 190,000 integral membrane phosphoglycoprotein that is overexpressed in some drug-selected resistant cell lines
|
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
|
| Subculturing： | Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended
Medium Renewal: 3 to 5 times per week as culture becomes acidic |
| Cryopreservation： | Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: Liquid nitrogen vapor phase |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X CSF1PO: 10,12 D13S317: 12 D16S539: 11 D5S818: 11,13 D7S820: 9 THO1: 8,9 TPOX: 10 vWA: 16,17 |
| Population Doubling Time： | 24 hrs |
| Name of Depositor： | S Cole |
| Deposited As： | human |
| U.S. Patent Number： | |
| References： | Deeley RG, Cole SP. Antibodies to a multidrug resistance protein. US Patent 6,063,621 dated May 16 2000 Hipfner DR, et al. Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res. 54: 5788-5792, 1994. PubMed: 7954400 Mirski SE, et al. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res. 47: 2594-2598, 1987. PubMed: 2436751 |